A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction

Patient level data analysis of 4 trials found that the treatment benefits of sacubitril/valsartan on cardiovascular events appear to be beneficial across the full range of left ventricular ejection fractions (LVEF), with most pronounced effects observed at a LVEF <60%.

European Heart Journal